The Viborg vascular (VIVA) screening trial of 65-74 year old men in the central region of Denmark: Study protocol

Trials

Volumn 11, Issue , 2010, Pages

  Grøndal, Nikolaj ^a   Søgaard, Rikke ^b   Henneberg, Eskild W ^a   Lindholt, Jes S ^a  

^a VIBORG HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL AORTA ANEURYSM; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DENMARK; EARLY DIAGNOSIS; FOLLOW UP; HOSPITALIZATION COST; HUMAN; HYPERTENSION; MALE; MORTALITY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCREENING; COST BENEFIT ANALYSIS; ECONOMICS; MASS SCREENING; METHODOLOGY; PUBLIC HEALTH; QUESTIONNAIRE;

AGED; AORTIC ANEURYSM, ABDOMINAL; COST-BENEFIT ANALYSIS; DENMARK; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MASS SCREENING; NATIONAL HEALTH PROGRAMS; PERIPHERAL VASCULAR DISEASES; PREVALENCE; QUESTIONNAIRES;

EID: 77954045355     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-67     Document Type: Article

References (22)

1. Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ 2005, 330:750. 10.1136/bmj.38369.620162.82, 555873, 15757960.
2. Ehlers L, Overvad K, Sorensen J, Christensen S, Bech M, Kjolby M. Analysis of cost effectiveness of screening Danish men aged 65 for abdominal aortic aneurysm. BMJ 2009, 338:b2243. 10.1136/bmj.b2243, 19553267.
3. The Danish health economic modelling study on AAA screening is flawed. , http://www.bmj.com/cgi/eletters/338/jun24_2/b2243#216533
4. Thompson SG, Ashton HA, Gao L, Scott RA. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ 2009, 338:b2307. 10.1136/bmj.b2307, 19553269.
5. Smoking, lung function and the prognosis of abdominal aortic aneurysm. The UK Small Aneurysm Trial Participants. Eur J Vasc Endovasc Surg 2000, 19:636-642. 10.1053/ejvs.2000.1066, 10873733.
6. Cornuz J, Sidoti PC, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Public Health 2004, 14:343-349. 10.1093/eurpub/14.4.343, 15542867.
7. Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, ngles-Cano E, Michel JB. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am J Pathol 2002, 161:1701-1710. 1850780, 12414517.
8. Touat Z, Ollivier V, Dai J, Huisse MG, Bezeaud A, Sebbag U, Palombi T, Rossignol P, Meilhac O, Guillin MC, Michel JB. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 2006, 168(3):1022-30. 10.2353/ajpath.2006.050868, 1606522, 16507915.
9. Lindholt JS, Sorensen HT, Michel JB, Thomsen HF, Henneberg EW. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg 2008, 42:329-334. 10.1177/1538574408315205, 18728038.
10. Schouten O, van Laanen JHH, Boersma E, Vidakovic R, Feringa HHH, Dunkelgrün M, Bax JJ, Koning J, van Urk H, Poldermans D. Statins are Associated with a Reduced Infrarenal Abdominal Aortic Aneurysm Growth. Eur J Vasc Endovasc Surg 2006, 32:21-26. 10.1016/j.ejvs.2005.12.024, 16520071.
11. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006, 368:659-665. 10.1016/S0140-6736(06)69250-7, 16920471.
12. Lindholt JS. Relatively high pulmonary and cardiovascular mortality rates in screening-detected aneurysmal patients without previous hospital admissions. Eur J Vasc Endovasc Surg 2007, 33:94-99. 10.1016/j.ejvs.2006.06.007, 16893664.
13. Diehm C, Kareem S, Lawall H. Epidemiology of peripheral arterial disease. Vasa 2004, 33:183-189. 10.1024/0301-1526.33.4.183, 15623192.
14. McDermott MM. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med 2006, 73(Suppl 4):S2-S7. 10.3949/ccjm.73.Suppl_4.S2, 17385385.
15. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, , Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. TASC II Working Group Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007, 33(Suppl 1):S1-75. 10.1016/j.ejvs.2006.09.024, 17140820, TASC II Working Group.
16. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Reimer Scholte op W, Weissberg P, Wood D, Yarnell J, Zamorano JL, , Walma E, Fitzgerald T, Cooney MT, Dudina A, , Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Hellemans I, Altiner A, Bonora E, Durrington PN, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen SE, Larsen ML, Mancia G, Manolis AJ, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef AF, Tokgözoglu L, Wiklund O, Zampelas A. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts), Other experts who contributed to parts of the guidelines, European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007, 28:2375-2414. 10.1093/eurheartj/ehm316, 17726041, Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts), Other experts who contributed to parts of the guidelines, European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG).
17. Sorensen J, Davidsen M, Gudex C, Pedersen KM, Bronnum-Hansen H. Danish EQ-5D population norms. Scand J Public Health 2009, 37:467-474. 10.1177/1403494809105286, 19535407.
18. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 2005, Oxford: Oxford University Press.
19. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002, 11:415-430. 10.1002/hec.678, 12112491.
20. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998, 18:S68-S80. 10.1177/0272989X9801800209, 9566468.
21. Moussa ID, Jaff MR, Mehran R, Gray W, Dangas G, Lazic Z, Moses JW. Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: the Peripheral Arterial Disease in Interventional Patients Study. Catheter Cardiovasc Interv 2009, 73:719-724. 10.1002/ccd.21969, 19213068.
22. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, Wahlberg E. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 2007, 45:1185-1191. 10.1016/j.jvs.2007.02.004, 17543683.